---
title: "Dr. Reddy’s Laboratories Releases Q2 FY2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262680307.md"
description: "Dr. Reddy’s Laboratories (RDY) announced its Q2 FY2026 financial results on October 24, 2025, during a board meeting. The results comply with International Financial Reporting Standards and Indian Accounting Standards, providing insights into the company's financial health. Analysts rate RDY stock as a Buy with a $16.00 price target. Spark's AI Analyst rates RDY as Outperform, highlighting strong financial performance and a balanced valuation. The company faces growth opportunities and challenges in the U.S. generics market. Dr. Reddy’s Laboratories is a leading pharmaceutical company based in Hyderabad, India, focusing on affordable medications."
datetime: "2025-10-24T19:27:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262680307.md)
  - [en](https://longbridge.com/en/news/262680307.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262680307.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/262680307.md) | [繁體中文](https://longbridge.com/zh-HK/news/262680307.md)


# Dr. Reddy’s Laboratories Releases Q2 FY2026 Financial Results

Dr Reddy’s Laboratories ( (RDY) ) has issued an update.

On October 24, 2025, Dr. Reddy’s Laboratories announced the approval of its unaudited financial results for the quarter and half-year ending September 30, 2025, during a board meeting. The results were prepared in compliance with both International Financial Reporting Standards and Indian Accounting Standards. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

**Spark’s Take on RDY Stock**

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories’ overall stock score reflects strong financial performance and a balanced valuation. The company’s consistent profitability and solid balance sheet are significant strengths. Technical analysis presents mixed signals, with short-term bullish momentum but potential bearish trends. The valuation is fair, with no significant overvaluation concerns. Earnings call insights highlight both growth opportunities and challenges, particularly in the U.S. generics market.

To see Spark’s full report on RDY stock, click here.

**More about Dr Reddy’s Laboratories**

Dr. Reddy’s Laboratories Limited is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the production and distribution of generic medications, active pharmaceutical ingredients, and proprietary products. The company is focused on providing affordable and innovative medicines to patients worldwide, with a significant presence in both emerging and developed markets.

**Average Trading Volume:** 1,052,372

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** $12.25B

Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [Dr. Reddy's Laboratories Limited (RDY.US)](https://longbridge.com/en/quote/RDY.US.md)

## Related News & Research

- [India gets cheap GLP-1 drugs: What you must know before trying it](https://longbridge.com/en/news/280274694.md)
- [10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt](https://longbridge.com/en/news/280097750.md)
- [$100 Invested In ProShares Ultra Silver 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/281548227.md)
- [Why Is Silver Down 4% Today, 4/2/26?](https://longbridge.com/en/news/281547191.md)
- [Iridium Communications Stock (IRDM) Moonshots 12% on SpaceX IPO Filing and Amazon Takeover Rumors](https://longbridge.com/en/news/281548482.md)